"Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL." by David Andorsky

Article

Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.

Journal of Clinical Oncology (2018)

David Andorsky, Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO;
Morton Coleman, Cornell University
Abdulraheem Yacoub, University of Kansas
Jason M. Melear, Texas Oncology
Heather Dawn Brooks, Oncology and Hematology Associates, US Oncology Research, Roanoke, VA;
Suzanne R. Fanning, Greenville Health System
Kathryn S. Kolibaba, Compass Oncology, US Oncology Research, Vancouver, WA;
Frederick Lansigan, Dartmouth–Hitchcock Medical Center
Chris Reynolds, IHA Hematology Oncology Consultants – Ann Arbor, Ypsilanti, MI;
Jiahui Li, Celgene
Dongfang Liu, Celgene
Mary Llorente, Celgene
Justin L. Ricker, Celgene
Jeff Porter Sharman, Willamette University

Link

Disciplines

Publication Date

June 1, 2018

DOI

10.1200/JCO.2018.36.15_SUPPL.7516

Citation Information

David Andorsky, Morton Coleman, Abdulraheem Yacoub, Jason M. Melear, et al.. "Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL." Journal of Clinical Oncology Vol. 36 (2018) p. 7516 - 7516
Available at: http://works.bepress.com/heather-brooks2/3/